Bouke P C Hazenberg

List of Publications by Year
in descending order

101 papers	6,996 citations	94269 37 h-index	58464 82 g-index
106 all docs	106 docs citations	106 times ranked	6242 citing authors

#	Article	IF	Citations
1	Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 2016, 133, 2404-2412.	1.6	1,335
2	Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology, 2005, 79, 319-328.	2.0	1,179
3	The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochemical and Biophysical Research Communications, 1988, 155, 112-117.	1.0	252
4	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	13.9	240
5	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2019, 26, 2065-2123.	1.4	230
6	Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. Journal of Clinical Investigation, 2008, 118, 3208-18.	3.9	205
7	Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Critical Care Medicine, 1992, 20, 185-192.	0.4	194
8	Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis and Rheumatism, 2006, 54, 2015-2021.	6.7	193
9	First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current Opinion in Neurology, 2016, 29, S14-S26.	1.8	179
10	Diagnostic Performance of 123I-Labeled Serum Amyloid P Component Scintigraphy in Patients with Amyloidosis. American Journal of Medicine, 2006, 119, 355.e15-355.e24.	0.6	129
11	Bone scintigraphy with^{99m}technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 35-44.	1.4	129
12	Amyloidosis. Rheumatic Disease Clinics of North America, 2013, 39, 323-345.	0.8	122
13	Cryo-EM fibril structures from systemic AA amyloidosis reveal the species complementarity of pathological amyloids. Nature Communications, 2019, 10, 1104.	5.8	113
14	Erythrocyte sedimentation rate, Câ€reactive protein level, and serum amyloid A protein for patient selection and monitoring of antiâ€"tumor necrosis factor treatment in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 61, 1484-1490.	6.7	112
15	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Journal of Cardiac Failure, 2019, 25, e1-e39.	0.7	107
16	Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1091, 405-408.	1.9	105
17	Improvement of lipid profile is accompanied by atheroprotective alterations in highâ€density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis. Arthritis and Rheumatism, 2009, 60, 1324-1330.	6.7	101
18	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2â€"Diagnostic criteria and appropriate utilization. Journal of Nuclear Cardiology, 2020, 27, 659-673.	1.4	97

#	Article	IF	Citations
19	Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1945-1955.	3.3	96
20	The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 1	1.2	90
21	Nuclear imaging in cardiac amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 702-714.	3.3	84
22	Laryngeal Amyloidosis: Localized versus Systemic Disease and Update on Diagnosis and Therapy. Annals of Otology, Rhinology and Laryngology, 2004, 113, 741-748.	0.6	75
23	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Journal of Cardiac Failure, 2019, 25, 854-865.	0.7	70
24	Causes of AA amyloidosis: a systematic review. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 1-12.	1.4	69
25	Where has secondary amyloid gone?. Annals of the Rheumatic Diseases, 2000, 59, 577-579.	0.5	67
26	Obesity-induced chronic inflammation in high fat diet challenged C57BL/6J mice is associated with acceleration of age-dependent renal amyloidosis. Scientific Reports, 2015, 5, 16474.	1.6	62
27	SjÃ¶gren's syndrome and localized nodular cutaneous amyloidosis: Coincidence or a distinct clinical entity?. Arthritis and Rheumatism, 2008, 58, 1992-1999.	6.7	61
28	Clinical and therapeutic aspects of AA amyloidosis. Bailliere's Clinical Rheumatology, 1994, 8, 661-690.	1.0	55
29	AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 165-174.	1.4	51
30	123I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1609-1617.	3.3	49
31	Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1095-1101.	3.3	49
32	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2â€"Evidence Base and Standardized Methods of Imaging. Circulation: Cardiovascular Imaging, 2021, 14, e000029.	1.3	48
33	A quantitative method for detecting deposits of amyloid A protein in aspirated fat tissue of patients with arthritis. Annals of the Rheumatic Diseases, 1999, 58, 96-102.	0.5	45
34	Diagnostic Performance and Prognostic Value of Extravascular Retention of 123I-Labeled Serum Amyloid P Component in Systemic Amyloidosis. Journal of Nuclear Medicine, 2007, 48, 865-872.	2.8	45
35	Lower Serum Paraoxonase-1 Activity Is Related to Higher Serum Amyloid A Levels in Metabolic Syndrome. Archives of Medical Research, 2011, 42, 219-225.	1.5	45
36	Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. European Heart Journal, 2002, 23, 157-161.	1.0	40

#	Article	IF	Citations
37	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	1.0	39
38	Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis, 2007, 28, 2053-2064.	1.3	37
39	Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Annals of the Rheumatic Diseases, 2002, 61, 42-47.	0.5	36
40	Increased plasmin-Î±2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. Journal of Thrombosis and Haemostasis, 2007, 5, 1139-1142.	1.9	36
41	Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 133-140.	1.4	35
42	Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2â€"evidence base and standardized methods of imaging. Journal of Nuclear Cardiology, 2021, 28, 1769-1774.	1.4	34
43	Histological regression of amyloid in AL amyloidosis is exclusively seen after normalization of serum free light chain. Haematologica, 2009, 94, 1094-1100.	1.7	32
44	Long-term follow-up after surgery in localized laryngeal amyloidosis. European Archives of Oto-Rhino-Laryngology, 2016, 273, 2613-2620.	0.8	31
45	Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care and Research, 2010, 62, 296-301.	1.5	30
46	Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. Nephrology Dialysis Transplantation, 2002, 17, 1212-1217.	0.4	29
47	Sensitive and rapid assessment of amyloid by oligothiophene fluorescence in subcutaneous fat tissue. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 19-25.	1.4	28
48	Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2018, 57, 1812-1821.	0.9	28
49	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 50-55.	1.4	28
50	Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial. Haematologica, 2019, 104, 2274-2282.	1.7	27
51	Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 243-251.	1.4	25
52	Laryngeal presentation of systemic apolipoprotein Aâ€Iâ€“derived amyloidosis. Laryngoscope, 2009, 119, 608-615.	1.1	24
53	Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 8-13.	1.4	24
54	Familial amyloidotic polyneuropathy: long-term follow-up of abdominal fat tissue aspirate in patients with and without liver transplantation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 221-226.	1.4	23

#	Article	IF	Citations
55	Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology, 2011, 50, 1925-1926.	0.9	23
56	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. American Journal of Cardiology, 2018, 121, 107-112.	0.7	22
57	Imaging cardiac innervation in amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 174-187.	1.4	21
58	Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2004, 11, 44-49.	1.4	20
59	Quality of life in patients with familial amyloidotic polyneuropathy long-term after liver transplantation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 133-141.	1.4	19
60	Morphological and primary structural consistency of fibrils from different AA patients (common) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Journal of the International Society of Amyloidosis, 2019, 26, 164-170.	1.4	19
61	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. Haematologica, 2015, 100, 677-682.	1.7	18
62	ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2â€"Diagnostic Criteria and Appropriate Utilization. Circulation: Cardiovascular Imaging, 2021, 14, e000030.	1.3	16
63	Nuclear imaging for cardiac amyloidosis. Heart Failure Reviews, 2015, 20, 145-154.	1.7	15
64	Imaging cardiac innervation in hereditary transthyretin (ATTRm) amyloidosis: A marker for neuropathy or cardiomyopathy in case of heart failure?. Journal of Nuclear Cardiology, 2020, 27, 1774-1784.	1.4	14
65	Kidney Involvement in Systemic Calcitonin Amyloidosis Associated With Medullary Thyroid Carcinoma. American Journal of Kidney Diseases, 2017, 69, 546-549.	2.1	12
66	Time for new imaging and therapeutic approaches in cardiac amyloidosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1402-1406.	3.3	12
67	The assessment of autonomic function in patients with systemic amyloidosis: methodological considerations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1998, 5, 193-199.	1.4	10
68	Monoclonal Antibody Based ELISA for Human SAA. , 1991, , 898-901.		9
69	Acute neuromyopathy after colchicine treatment.. Annals of the Rheumatic Diseases, 1992, 51, 1267-1268.	0.5	8
70	Clinical use of differential nuclear medicine modalities in patients with ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 208-211.	1.4	8
71	Transthyretin-Derived (ATTR) Amyloidotic Cardiomyopathy After Receiving a Domino Liver Allograft. Circulation, 2015, 132, e216-7.	1.6	8
72	Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 227-233.	1.4	7

#	Article	IF	Citations
73	Annual evaluation of hip joints and hands for radiographic signs of A?2M-amyloidosis in long-term hemodialysis patients. Skeletal Radiology, 1994, 23, 421-7.	1.2	6
74	A Dutch kindred with familial amyloidotic polyneuropathy associated with the trans thy retin Cys 114 mutant. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1997, 4, 112-117.	1.4	6
75	Transthyretin Val71Ala mutation in a Dutch family with familial amyloidotic polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2000, 7, 218-221.	1.4	6
76	Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma. Thrombosis and Haemostasis, 2018, 118, 471-479.	1.8	6
77	Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis. Orphanet Journal of Rare Diseases, 2019, 14, 220.	1.2	6
78	Biology/Disease-Driven Initiative on Protein-Aggregation Diseases of the Human Proteome Project: Goals and Progress to Date. Journal of Proteome Research, 2018, 17, 4072-4084.	1.8	5
79	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Cardiovascular Pathology, 2017, 29, 19-22.	0.7	3
80	Muscle mass versus body mass index as predictor of adverse outcome. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 517-518.	2.9	3
81	Fat Tissue Analysis in the Management of Patients with Systemic Amyloidosis. , 2012, , 191-207.		3
82	High-Dose Therapy in AL Amyloidosis: A Prospective Phase II Study by the Dutch-Belgian Cooperative Group (HOVON). Blood, 2008, 112, 163-163.	0.6	2
83	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	1.2	2
84	In memoriam Enno Mandema, MD (1921-2010). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 249-250.	1.4	1
85	Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 56-57.	1.4	1
86	Fluorine-18 labeled fluorodeoxyglucose PET useful for therapy monitoring in localized AL amyloidosis?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 135-137.	1.4	1
87	Additional diagnostic value of SPECT/CT to planar Iodine-123 labeled serum amyloid P component scintigraphy in a patient with pulmonary nodular amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 131-133.	1.4	1
88	99mTc-aprotinin imaging in cardiac amyloidosis. Make an old tool new again?. Journal of Nuclear Cardiology, 2020, 27, 1155-1157.	1.4	1
89	A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 119-127.	1.4	1
90	Fat Tissue Analysis in the Management of Patients with Systemic Amyloidosis. Current Clinical Pathology, 2015, , 229-248.	0.0	1

#	Article	IF	Citations
91	HOVON 104; Results of First 25 Patients from a Multicenter, Multinational, Prospective Phase II Study of Bortezomib Based Induction Treatment Followed By Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Al Amyloidosis. Blood, 2016, 128, 4628-4628.	0.6	1
92	Novel treatments for systemic amyloidosis. International Journal of Clinical Rheumatology, 2009, 4, 171-188.	0.3	1
93	High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. New England Journal of Medicine, 2008, 358, 92; author reply 92-3.	13.9	1
94	A homozygous M694V mutation of the MEFV gene in a patient with periodic fever and thoracic pain. Netherlands Journal of Medicine, 2000, 56, 21-24.	0.6	0
95	Echocardiographic features of an atypical presentation of rapidly progressive cardiac amyloidosis. World Journal of Cardiology, 2013, 5, 154.	0.5	0
96	Cardiac diphosphonate uptake. Heart, 2014, 100, 1192-1192.	1.2	0
97	Diagnostic accuracy of new indirect ELISAs for free light-chain quantification in fat tissue of patients with AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 46-47.	1.4	0
98	Clinical and 123I-SAP scintigraphy findings in three members from a family affected by AGel amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 155-156.	1.4	0
99	Coexistence of wild type and hereditary ATTR amyloidosis in one family. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 71-72.	1.4	0
100	Crp and SAA Serum Levels in Chronic Active Hepatitis. , 1991, , 825-826.		0
101	Imaging of the Autonomic Nervous System in Cardiac Amyloidosis. , 2015, , 321-335.		0